+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Neurotransmitter"

From
Cognitive and Memory Enhancer Drugs Market 2025-2033 - Product Thumbnail Image

Cognitive and Memory Enhancer Drugs Market 2025-2033

  • Report
  • March 2025
  • 139 Pages
  • Global
From
Trichotillomania (TTM) Epidemiology Forecast 2025-2034 - Product Thumbnail Image

Trichotillomania (TTM) Epidemiology Forecast 2025-2034

  • Report
  • May 2025
  • 150 Pages
  • Global
From
From
Infantile Spasm Epidemiology Forecast 2025-2034 - Product Thumbnail Image

Infantile Spasm Epidemiology Forecast 2025-2034

  • Report
  • May 2025
  • 150 Pages
  • Global
From
Seizures Pipeline Insight Analysis Report - Product Thumbnail Image

Seizures Pipeline Insight Analysis Report

  • Drug Pipelines
  • August 2024
  • 150 Pages
  • Global
From
Ionotropic Glutamate Receptor Antagonists - Pipeline Insight, 2025 - Product Thumbnail Image

Ionotropic Glutamate Receptor Antagonists - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 100 Pages
  • Global
From
Glutamate Receptor Antagonists - Pipeline Insight, 2025 - Product Thumbnail Image

Glutamate Receptor Antagonists - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
5-HT1D Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

5-HT1D Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Myotonic Dystrophy - Pipeline Insight, 2025 - Product Thumbnail Image

Myotonic Dystrophy - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
Parkinson's Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Parkinson's Disease - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 280 Pages
  • Global
From
Autistic Disorder- Pipeline Insight, 2025 - Product Thumbnail Image

Autistic Disorder- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
5-HT2 Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

5-HT2 Agonist - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
Epilepsy - Pipeline Insight, 2025 - Product Thumbnail Image

Epilepsy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 280 Pages
  • Global
From
Migraine - Pipeline Insight, 2025 - Product Thumbnail Image

Migraine - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Subarachnoid Hemorrhage- Pipeline Insight, 2025 - Product Thumbnail Image

Subarachnoid Hemorrhage- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Spinocerebellar Ataxias - Pipeline Insight, 2025 - Product Thumbnail Image

Spinocerebellar Ataxias - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Essential Tremor - Pipeline Insight, 2025 - Product Thumbnail Image

Essential Tremor - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
Dopamine D1 Receptor Antagonists - Pipeline Insight, 2025 - Product Thumbnail Image

Dopamine D1 Receptor Antagonists - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

The Neurotransmitter market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Neurotransmitters are chemicals that are released by neurons to send signals to other cells. These drugs are used to treat a variety of neurological disorders, including depression, anxiety, and schizophrenia. Neurotransmitter drugs work by either increasing or decreasing the amount of neurotransmitters in the brain. The Neurotransmitter market is highly competitive, with many companies offering a variety of drugs. Some of the major players in the market include Pfizer, GlaxoSmithKline, Eli Lilly, and Merck. Other companies such as Novartis, AstraZeneca, and Johnson & Johnson also have a presence in the Neurotransmitter market. Show Less Read more